Selective inhibition of 'motor endplate-specific' acetylcholinesterase by beta-endorphin and related peptides

The effect of continuous pyridostigmine administration on functional (A12) acetylcholinesterase activity in guinea-pig muscles

Pyridostigmine which causes a reversible inhibition of acetylcholinesterase (AChE), was administered continuously for 6 days to guinea-pigs, via a subcutaneously implanted osmotic pump. This produced 40-50% inhibition of red cell acetylcholinesterase (AChE). Controls were animals treated with saline via pumps, and untreated animals. The activities of the functional A12 molecular form of AChE were compared in diaphragm, extensor digitorum longus (EDL) and soleus muscles in the three animal groups at 6 days. The pumps were removed at 6 days and the A12 AChE activities were determined at various times thereafter As the enzyme separation procedure was lengthy, drug-induced inhibition was no longer present when the enzyme activity was measured. At 6 days, the activity was significantly higher in EDL (over 50% higher) and soleus (over two-fold higher) in pyridostigmine-treated animals than saline-treated animals. In the diaphragm, the activities in pyridostigmine and saline-treated animals were similar but both were significantly (over two-fold) higher than in untreated animals. At 1 day after pump removal (day 7) the activity had declined in all three muscles of the pyridostigmine-treated animals and in the diaphragm of saline-treated animals. Thereafter, in the diaphragm (but not the EDL or soleus) in pyridostigmine-treated animals, there were marked variations in the enzyme activity up to day 20. In saline-treated animals there was a marked transient increase in activity at day 13 in all muscles. The results indicate that the homeostatic control offunctional AChE had been affected in both the pyridostigmine and saline treatment groups.

Effects of pyridostigmine on acetylcholinesterase in different muscles of the mouse

1. Pyridostigmine bromide was administered subcutaneously in mice, in a dose of 4.0 or 2.0 mu moles/kg, and the activity of the predominant (G1, G4 and A12) molecular forms of acetylcholinesterase were examined in diaphragm, extensor digitorum longus (EDL), and soleus muscles at 3 h, 6 h, 24 h and 5 days. 2. In diaphragm, no effect was apparent after the low dose, but after the high dose there was a reduction in activity of the functional A12 form at 24 h, followed by an increase which had overshot the control level at 5 days. 3. In the fast EDL, after the low dose, all three molecular forms were decreased at 3 h but had returned to normal by 6 h. This effect was not apparent after the high dose. 4. In the slow soleus the low dose caused a significant increase in total enzyme activity at 5 days, but the high dose caused significant increases in all molecular forms at 3 hours. 5. Thus pyridostigmine had delayed effects on the levels of acetylcholinesterase. The three muscles displayed different sensitivities to the drug, but the changes were consistent with initial inhibition of the activity leading to down-regulation of the enzyme followed by up-regulation, which could overshoot the normal levels.

Actions of beta-endorphin peptides on the contractions of mouse diaphragm muscle

The effect of derivatives of beta-endorphin on the contractile response to indirect stimulation in mouse diaphragm muscle was studied to determine whether the action of the peptide to increase muscle tension is an opioid effect. beta-Endorphin (1-27), beta-endorphin (30-31), and a beta-endorphin (28-31) analogue all increased the amplitude of the contractions. The C-terminal peptides were more potent than beta-endorphin or beta-endorphin (1-27). The beta-endorphin (28-31) analogue, like beta-endorphin, decreased the time to peak but beta-endorphin (1-27) did not. The effect of beta-endorphin (1-27), but not that of the beta-endorphin (28-31) analogue, was blocked by naloxone. Thus, beta-endorphin acts on muscle via both opioid and nonopioid receptors.

Distribution of opioid peptide receptors in muscles of lean and obese-diabetic mice

Autoradiography was used to demonstrate beta-endorphin and delta-opioid receptors in muscles of normal and obese-diabetic mice. The density of the receptors was significantly higher in the obese-diabetic mice. In both normal and diabetic mice, glycolytic and oxidative fibers exhibited the beta-endorphin receptors. However, a significantly greater density of beta-endorphin receptors was observed in the extensor digitorum longus muscles than in the soleus muscles in the diabetic mice. In normal muscles the beta-endorphin receptors were largely restricted to regions where endplates were present, but in the obese-diabetic mice they were densely distributed along the length of the muscle fibers.

The effect of opiates on the terminal nerve impulse and quantal secretion from visualized amphibian nerve terminals

1. Secretion of transmitter from amphibian motor nerve terminal release sites is intermittent, spatially non-uniform and varies considerably throughout the year and during development. The role of opioid receptors in modulating transmitter secretion from amphibian motor nerve terminals is evaluated in this study. 2. Dynorphin-A (24 microM) and morphine (500 microM) did not significantly change the shape of the nerve impulse or the consistency with which it was observed, but decreased evoked quantal secretion by more than 50%. These effects of dynorphin-A and morphine were largely reversed by naloxone (50 microM). 3. Dynorphin-A and morphine did not significantly change either the amplitude or the frequency of spontaneous quantal secretions. 4. There was a uniform decrease in evoked quantal secretion from release sites along terminal branches, irrespective of the quantal content value before drug treatment, indicating no difference in the susceptibility of proximal vs distal release sites to opiates. 5. Increasing the extracellular calcium concentration (0.3 to 0.4 mM) or trains of conditioning-test impulses (25 to 100 Hz) resulted in smaller dynorphin-A or morphine-induced decreases in evoked quantal secretion. 6. The decrease in evoked quantal secretion occurs as a result of a uniform decrease in the probability of quantal secretion from release sites without any affect on the propagation of the nerve terminal impulse. Low probability release sites become effectively silent.

The effect of opiates on the secretion of transmitter from amphibian motor nerve terminals

The effects of dynorphin-A, dermorphine and morphine on the secretion of transmitter from the toad (Bufo marinus) motor nerve terminal have been determined. Intracellular recordings of miniature end plate potentials (m.e.p.p.s) and evoked end plate potentials (e.p.p.s) were used to estimate quantal content (m) and binomial parameters p and n. Dynorphin-A, and to a lesser extent morphine, decreased (m) while dermorphine had no significant effect on m. Dynorphin-A (ED50 = 24 microM) was 21 times more potent then morphine (ED50 = 510 microM) in decreasing m. The decrease in m produced by dynorphin-A and morphine was accompanied by a greater decrease in the variance (S2) of number of quanta secreted per stimulation over the recording period. The decrease in m produced by dynorphin-A, and to a lesser extent by morphine, is probably mediated by the opiates acting on kappa-opioid receptors.

Glycyl-L-glutamine stimulates the accumulation of A12 acetylcholinesterase but not of nicotinic acetylcholine receptors in quail embryonic myotubes by a cyclic AMP-independent mechanism

Myotubes prepared from the Japanese quail embryo at 9 days gestation were cultivated in the presence of glycyl-L-glutamine (Gly-Gln, beta-endorphin C-terminal dipeptide) or glycyl-glutamic acid (Gly-Glu), and changes in the activity of acetylcholinesterase (AChE) molecular forms and binding of 125I-alpha-bungarotoxin (alpha BGT) to cell surface nicotinic acetylcholine receptors were measured. The A12 oligomer was the major form of AChE in the cultures. The activity of all molecular forms of the enzyme was increased in the presence of Gly-Gln, but Gly-Glu did not alter AChE activity. In cells infected with the temperature-sensitive mutant, La31C, of Rous sarcoma virus (ts-RSV) and transferred to the nonpermissive temperature, the A12 form of AChE was absent, but its activity could be induced following exposure of the cells to Gly-Gln. When cells treated in this way were incubated in the presence of collagenase, there was a small but significant loss of A12 AChE activity, indicating that Gly-Gln stimulated the activity of a pool of this oligomer which was mainly but not entirely intracellular. Neither Gly-Gln nor Gly-Glu influenced 125I-alpha BGT binding after exposure of the cells to the peptides for any duration. Neither Gly-Gln nor Gly-Glu influenced the accumulation of cyclic AMP in the cultures. beta-Endorphin is one of a family of peptides that coexist transiently with acetylcholine in lower motoneurones of vertebrates in the perinatal period. This report provides evidence for the selective trophic activity of one of its derivatives toward the postsynaptic cholinergic system in avian muscle cells.

Presence of alpha-melanocyte-stimulating hormone-like immunoreactivity in the innervation of amphibian skeletal muscle

Amphibian motor nerve terminals are sensitive to a wide variety of peptides, including alpha-melanocyte-stimulating hormone (alpha-MSH). We determined the presence and distribution of alpha-MSH-like immunoreactivity (alpha-MSHLI) in the innervation of the cutaneous pectoris muscle from bullfrog (Rana catesbeiana) tadpoles and postmetamorphic froglets, and adult frogs (R. catesbeiana and R. pipiens). alpha-MSHLI was found in unmyelinated, noncholinergic axons, in motor axons, and in motor nerve terminals. In motor axons, alpha-MSHLI was predominantly associated with neurofilaments. The distribution of this form of alpha-MSHLI changed during development and seasonally in adult frogs. The possible functional roles of this alpha-MSHLI are discussed.

Castration and tolerance induces changes in the levels of the activity of acetylcholinesterase in the isolated vas deferens of the rat

Changes in the activity of acetylcholinesterase (AChE) of the isolated vas deferens from normal, castrated, morphine and ethanol-tolerant rats were studied. Three days after the termination of treatment with morphine and on the last day of treatment with ethanol, a significant inhibition of the activity of AChE was detected. This reduction in the enzymatic activity persisted in morphine-tolerant rats for 15 days, but not for 30 days, at which time the levels of AChE were determined to be normal. However, in ethanol-tolerant rats, there were no significant changes found at days 15 or 30. The activity of AChE was decreased significantly in castrated rats, but this effect was reversed by treatment with testosterone. During withdrawal from morphine or ethanol, the levels of AChE were significantly increased. The results indicate that morphine and ethanol may be inducing changes in the feedback mechanism which regulates the levels of AChE at post-synaptic sites, and these changes could play an important role in the development of tolerance to morphine and to ethanol.

Transient expression of adenosine deaminase in facial and hypoglossal motoneurons of the rat during development

Immunohistochemical and retrograde tracing techniques were employed to demonstrate a changing pattern of adenosine deaminase (ADA) immunoreactivity in cranial motoneurons during their ontogenesis in the rat. Immunostaining for ADA was observed only in motoneurons of hypoglossal and facial motor nuclei and only at certain stages during development. Moreover, ADA immunoreactivity was restricted to subpopulations of motoneurons within each nucleus. In the hypoglossal nucleus ADA-immunostained neurons were seen only in the dorsal subnucleus, where they appeared at about 15 days of gestation, reached maximal staining intensity early after birth, and disappeared by the 25th postnatal day. In the facial motor nucleus, immunoreactive neurons were detected only in the intermediate subnucleus, where ADA immunostaining was first detected at 18 days of gestation and was maximal during the first few postnatal days, and in the lateral subnucleus, where immunostaining appeared perinatally. In both facial motor subnuclei, ADA immunoreactivity was no longer detectable by the 15th postnatal day. Retrograde tracing with WGA-HRP or fluorescent dye injected into various muscles of the face or tongue in young animals indicated that ADA-immunoreactive motoneurons in the hypoglossal and facial motor nuclei innervate retractor muscles of the tongue and perioral or nasal muscles, respectively. In view of the critical role of these muscles in suckling and sniffing behavior, it is suggested that metabolic pathways associated with ADA may be involved in the early maturation of the motoneurons projecting to these muscles. Alternatively, the transient presence of ADA in these neurons may reflect a developmental period during which purine nucleosides and/or nucleotides may serve as neuromodulators at their peripheral terminations.

Fasciculin II, a protein inhibitor of acetylcholinesterase, tested on central synapses of Aplysia

Fasciculin II, a potential inhibitor of acetylcholinesterase (AChE), was tested on two types of Aplysia cholinergic receptors: H type, opening Cl- channels; and D type, opening cationic channels. Evoked postsynaptic inhibitory responses and responses to ionophoretic application of acetylcholine (ACh) or carbachol onto H-type receptors were potentiated in the presence of fasciculin II at 10(-9) M, whereas the same concentration of this drug was without effect on the evoked postsynaptic excitatory responses or on the application of ACh or carbachol on D-type receptors. The observed effects of fasciculin II were identical to those obtained with other inhibitors of AChE on the same preparation. The facilitatory effect on the carbachol response in H-type cells indicates that fasciculin II, as other AChE inhibitors, does not act on H-type synapses solely by blocking the hydrolysis of ACh. We concluded that fasciculin II was a good inhibitor of acetylcholinesterase on neuronal preparations in vivo. The results are further discussed as a new element in favor of a previously proposed hypothesis of a molecular interaction between AChE and ACh H-type receptors.

Enkephalin and substance P modulate synaptic properties of chick ciliary ganglion neurons in cell culture

Since enkephalin- and substance P-like immunoreactive materials have been identified in preganglionic terminals of the avian ciliary ganglion, we tested the effects of enkephalin and substance P directly on chick ciliary ganglion neurons in dissociated cell culture. Under these conditions the neurons form cholinergic synapses with each other that are spontaneously active. Both peptides modulate properties of membrane components associated with synaptic transmission between the neurons. Enkephalin causes a 60% reduction in the mean amplitude of the excitatory synaptic potentials, and the effect appears to be presynaptic in origin: enkephalin does not alter acetylcholine sensitivity on the neurons, but does inhibit Ca2+ influx as reflected by a 38% shortening of the Ca2+ component of the action potential. Both the reduction in synaptic potential amplitude and the shortening of the Ca2+ action potential produced by enkephalin are blocked by naloxone. Substance P, on the other hand, has no effect on Ca2+ action potentials but does reduce the time course of acetylcholine responses in the neurons by a mechanism consistent with enhanced receptor desensitization. Decay of the acetylcholine voltage response in the absence of substance P is described by a single exponential process with a time constant of 4-5 s. Coapplication of acetylcholine and substance P results in a second exponential decay process with a time constant of about 1 s that appears after a 200-400 ms lag period. Preincubation with substance P alone does not decrease the peak voltage response or shorten the lag, suggesting that either agonist or activated receptor is necessary for the substance P effect. These findings suggest modulatory roles for the peptides in ganglionic transmission.

Actions of polypeptides at the neuromuscular junction

The effects of several polypeptides, e.g. angiotensin II, substance P, oxytocin and vasopressin, on the isolated frog gastrocnemius, chick biventer cervicis and rat hemodiaphragm preparations were studied using electrophysiological and neurochemical techniques. The effects of angiotensin II, substance P, oxytocin and vasopressin on neuromuscular transmission and muscle contraction were investigated by studying the following parameters: the directly and indirectly-elicited twitch and tetanic contractions, nerve compound action potential, uptake of 3H-methylcholine into nerve-muscle preparations, the contractures produced by depolarizing drugs, e.g. ACh or TEA. The results showed that angiotensin II (10(-10)-10(-6) M) and substance P (10(-7)-10(-6) M) enhanced neuromuscular transmission and muscle contraction by increasing the amplitudes of the indirectly-elicited twitch and tetanic contractions. Oxytocin and vasopressin (1-100 mU/ml-1) both depressed neuromuscular transmission by reducing the contractile and electrical response in the frog, chick and rat skeletal muscle. It was concluded that, like their effects on ganglionic transmission, the peptides can modify neuromuscular transmission. The mechanism by which these peptides produce their effects may be dependent on external calcium concentration. These peptides may affect both pre- and postjunctional mechanisms; prejunctionally by increasing/decreasing the release of ACh, and postjunctionally by affecting the sensitivity of the postjunctional membrane to depolarizing drugs and/or producing a contracture in the skeletal muscle.

Actions of polypeptides at the neuromuscular junction

The effects of several polypeptides, e.g. angiotensin II, substance P, oxytocin and vasopressin, on the isolated frog gastrocnemius, chick biventer cervicis and rat hemodiaphragm preparations were studied using electrophysiological and neurochemical techniques. The effects of angiotensin II, substance P, oxytocin and vasopressin on neuromuscular transmission and muscle contraction were investigated by studying the following parameters: the directly and indirectly-elicited twitch and tetanic contractions, nerve compound action potential, uptake of 3H-methylcholine into nerve-muscle preparations, the contractures produced by depolarizing drugs, e.g. ACh or TEA. The results showed that angiotensin II (10(-10)-10(-6) M) and substance P (10(-7)-10(-6) M) enhanced neuromuscular transmission and muscle contraction by increasing the amplitudes of the indirectly-elicited twitch and tetanic contractions. Oxytocin and vasopressin (1-100 mU/ml-1) both depressed neuromuscular transmission by reducing the contractile and electrical response in the frog, chick and rat skeletal muscle. It was concluded that, like their effects on ganglionic transmission, the peptides can modify neuromuscular transmission. The mechanism by which these peptides produce their effects may be dependent on external calcium concentration. These peptides may affect both pre- and postjunctional mechanisms; prejunctionally by increasing/decreasing the release of ACh, and postjunctionally by affecting the sensitivity of the postjunctional membrane to depolarizing drugs and/or producing a contracture in the skeletal muscle.

Presence of immunoreactive alpha-melanotropin and beta-endorphin in spinal motoneurones of the dystrophic mouse

Two derivatives of the stem hormone opiomelanocortin, alpha-melanotropin (alpha-MSH) and beta-endorphin, were detected immunocytochemically in the cell bodies and in the peripheral axon terminals of spinal motoneurones in immature but not in adult healthy mice. Immunoreactivity was demonstrated in motoneurones in both immature and adult mice with inherited muscular dystrophy. These results provide evidence for a motoneurone abnormality in murine dystrophy. The observations are discussed in the light of trophic influences over neuromuscular transmission which have been attributed to this family of neuropeptides.

Evidence for the neurotrophic regulation of collagen-tailed acetylcholinesterase in immature skeletal muscle by beta-endorphin

Acetylcholinesterase (AChE) was extracted in a high-saline medium from gastrocnemius muscles of rat embryos and young rats aged 14 days' gestation to 40 days post partum. The molecular forms of the enzyme were separated by low-salt precipitation, followed by velocity sedimentation. During gestation, all molecular forms increased in activity, particularly the 16 S (A12) form. During the first 2 weeks of life, there was a large increase in the activity of soluble AChE (G forms), whilst the activity of insoluble AChE (A forms) was reduced. Denervation of the muscle reversed the change in the relative proportions of the molecular forms. The embryonic pattern of activities of AChE forms persisted in cultures of myotubes obtained at 20 days' gestation and maintained in the absence of spinal cord. When myotubes were maintained in medium previously conditioned by developing spinal cord explants, 16 S AChE declined while the soluble (4 and 6 S) forms increased in activity in a manner resembling that seen in early postnatal muscles in vivo. beta-Endorphin (beta-EP) immunoreactivity was detected in the spinal cord-conditioned medium and was identified by HPLC and ion-exchange chromatography as beta-EP-(1-31) plus its shortened and N-acetylated forms. Cultivation of myotubes in the presence of synthetic camel beta-EP resulted in a reversible change in the pattern of AChE forms which was similar to that seen with spinal cord-conditioned medium. These studies provide evidence for the neuroregulation of AChE A and G forms in immature skeletal muscle. A major candidate for this role is beta-EP, produced and released by developing spinal cord.

Enkephalin reduces quantal content at the frog neuromuscular junction

Opiate peptides, particularly Met-enkephalin, have been shown to block or reduce Ca2+-dependent events in a variety of neurones. Our own observations on the effect of enkephalin on developing Rohon-Beard neurones in Xenopus spinal cord suggested that enkephalin might interact directly with Ca2+ channels in vertebrate neurones. This possibility prompted us to look for an effect of enkephalin on another population of neuronal Ca2+ channels--those in the presynaptic terminals at the frog neuromuscular junction. We were encouraged to try this preparation by an early report that morphine, in rather high concentrations, reduced the amount of acetylcholine (ACh) released from frog muscle by nerve stimulation. Our present results indicate that Met-enkephalin reversibly and specifically reduces the quantal content of transmitter release from nerve terminals in the frog cutaneous pectoris muscle, probably by means of an effect on inward Ca2+ current.